Global Hepatocellular Carcinoma Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
Published On: October 2018
 
Report ID:301294
 
 
Pages: 131




HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.

Scope of the Report:

This report focuses on the Hepatocellular Carcinoma Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2017. The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market. However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.

The worldwide market for Hepatocellular Carcinoma Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

Bayer

Eli Lilly

Johnson and Johnson

Pfizer

Bristol-Myers Squibb

Celgene

F. Hoffmann-la Roche

Gilead

GlaxoSmithKline

Merck

Novartis

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Brachytherapy

Chemotherapy

Local Ablation Therapy

Market Segment by Applications, can be divided into

Hospitals

Clinics

Cancer Rehabilitation Centers

There are 15 Chapters to deeply display the global Hepatocellular Carcinoma Drugs market.

Chapter 1, to describe Hepatocellular Carcinoma Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Hepatocellular Carcinoma Drugs, with sales, revenue, and price of Hepatocellular Carcinoma Drugs, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Hepatocellular Carcinoma Drugs, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Hepatocellular Carcinoma Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Hepatocellular Carcinoma Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Table of Contents

1 Market Overview

1.1 Hepatocellular Carcinoma Drugs Introduction

1.2 Market Analysis by Type

1.2.1 Brachytherapy

1.2.2 Chemotherapy

1.2.3 Local Ablation Therapy

1.3 Market Analysis by Applications

1.3.1 Hospitals

1.3.2 Clinics

1.3.3 Cancer Rehabilitation Centers

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Bayer

2.1.1 Business Overview

2.1.2 Hepatocellular Carcinoma Drugs Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Bayer Hepatocellular Carcinoma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Eli Lilly

2.2.1 Business Overview

2.2.2 Hepatocellular Carcinoma Drugs Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Eli Lilly Hepatocellular Carcinoma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Johnson and Johnson

2.3.1 Business Overview

2.3.2 Hepatocellular Carcinoma Drugs Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Johnson and Johnson Hepatocellular Carcinoma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Pfizer

2.4.1 Business Overview

2.4.2 Hepatocellular Carcinoma Drugs Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Pfizer Hepatocellular Carcinoma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 Bristol-Myers Squibb

2.5.1 Business Overview

2.5.2 Hepatocellular Carcinoma Drugs Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6 Celgene

2.6.1 Business Overview

2.6.2 Hepatocellular Carcinoma Drugs Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Celgene Hepatocellular Carcinoma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7 F. Hoffmann-la Roche

2.7.1 Business Overview

2.7.2 Hepatocellular Carcinoma Drugs Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.8 Gilead

2.8.1 Business Overview

2.8.2 Hepatocellular Carcinoma Drugs Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Gilead Hepatocellular Carcinoma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.9 GlaxoSmithKline

2.9.1 Business Overview

2.9.2 Hepatocellular Carcinoma Drugs Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 GlaxoSmithKline Hepatocellular Carcinoma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.10 Merck

2.10.1 Business Overview

2.10.2 Hepatocellular Carcinoma Drugs Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Merck Hepatocellular Carcinoma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.11 Novartis

2.11.1 Business Overview

2.11.2 Hepatocellular Carcinoma Drugs Type and Applications

2.11.2.1 Product A

2.11.2.2 Product B

2.11.3 Novartis Hepatocellular Carcinoma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Hepatocellular Carcinoma Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Hepatocellular Carcinoma Drugs Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Hepatocellular Carcinoma Drugs Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Hepatocellular Carcinoma Drugs Manufacturer Market Share in 2017

3.3.2 Top 6 Hepatocellular Carcinoma Drugs Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Hepatocellular Carcinoma Drugs Market Analysis by Regions

4.1 Global Hepatocellular Carcinoma Drugs Sales, Revenue and Market Share by Regions

4.1.1 Global Hepatocellular Carcinoma Drugs Sales and Market Share by Regions (2013-2018)

4.1.2 Global Hepatocellular Carcinoma Drugs Revenue and Market Share by Regions (2013-2018)

4.2 North America Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

4.3 Europe Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

4.5 South America Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

5 North America Hepatocellular Carcinoma Drugs by Countries

5.1 North America Hepatocellular Carcinoma Drugs Sales, Revenue and Market Share by Countries

5.1.1 North America Hepatocellular Carcinoma Drugs Sales and Market Share by Countries (2013-2018)

5.1.2 North America Hepatocellular Carcinoma Drugs Revenue and Market Share by Countries (2013-2018)

5.2 United States Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

5.3 Canada Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

5.4 Mexico Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

6 Europe Hepatocellular Carcinoma Drugs by Countries

6.1 Europe Hepatocellular Carcinoma Drugs Sales, Revenue and Market Share by Countries

6.1.1 Europe Hepatocellular Carcinoma Drugs Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Hepatocellular Carcinoma Drugs Revenue and Market Share by Countries (2013-2018)

6.2 Germany Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

6.3 UK Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

6.4 France Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

6.5 Russia Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

6.6 Italy Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

7 Asia-Pacific Hepatocellular Carcinoma Drugs by Countries

7.1 Asia-Pacific Hepatocellular Carcinoma Drugs Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Hepatocellular Carcinoma Drugs Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Hepatocellular Carcinoma Drugs Revenue and Market Share by Countries (2013-2018)

7.2 China Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

7.3 Japan Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

7.4 Korea Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

7.5 India Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

8 South America Hepatocellular Carcinoma Drugs by Countries

8.1 South America Hepatocellular Carcinoma Drugs Sales, Revenue and Market Share by Countries

8.1.1 South America Hepatocellular Carcinoma Drugs Sales and Market Share by Countries (2013-2018)

8.1.2 South America Hepatocellular Carcinoma Drugs Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

8.3 Argentina Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

8.4 Colombia Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

9 Middle East and Africa Hepatocellular Carcinoma Drugs by Countries

9.1 Middle East and Africa Hepatocellular Carcinoma Drugs Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Hepatocellular Carcinoma Drugs Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Hepatocellular Carcinoma Drugs Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

9.3 UAE Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

9.4 Egypt Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

9.5 Nigeria Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

9.6 South Africa Hepatocellular Carcinoma Drugs Sales and Growth Rate (2013-2018)

10 Global Hepatocellular Carcinoma Drugs Market Segment by Type

10.1 Global Hepatocellular Carcinoma Drugs Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Hepatocellular Carcinoma Drugs Sales and Market Share by Type (2013-2018)

10.1.2 Global Hepatocellular Carcinoma Drugs Revenue and Market Share by Type (2013-2018)

10.2 Brachytherapy Sales Growth and Price

10.2.1 Global Brachytherapy Sales Growth (2013-2018)

10.2.2 Global Brachytherapy Price (2013-2018)

10.3 Chemotherapy Sales Growth and Price

10.3.1 Global Chemotherapy Sales Growth (2013-2018)

10.3.2 Global Chemotherapy Price (2013-2018)

10.4 Local Ablation Therapy Sales Growth and Price

10.4.1 Global Local Ablation Therapy Sales Growth (2013-2018)

10.4.2 Global Local Ablation Therapy Price (2013-2018)

11 Global Hepatocellular Carcinoma Drugs Market Segment by Application

11.1 Global Hepatocellular Carcinoma Drugs Sales Market Share by Application (2013-2018)

11.2 Hospitals Sales Growth (2013-2018)

11.3 Clinics Sales Growth (2013-2018)

11.4 Cancer Rehabilitation Centers Sales Growth (2013-2018)

12 Hepatocellular Carcinoma Drugs Market Forecast (2018-2023)

12.1 Global Hepatocellular Carcinoma Drugs Sales, Revenue and Growth Rate (2018-2023)

12.2 Hepatocellular Carcinoma Drugs Market Forecast by Regions (2018-2023)

12.2.1 North America Hepatocellular Carcinoma Drugs Market Forecast (2018-2023)

12.2.2 Europe Hepatocellular Carcinoma Drugs Market Forecast (2018-2023)

12.2.3 Asia-Pacific Hepatocellular Carcinoma Drugs Market Forecast (2018-2023)

12.2.4 South America Hepatocellular Carcinoma Drugs Market Forecast (2018-2023)

12.2.5 Middle East and Africa Hepatocellular Carcinoma Drugs Market Forecast (2018-2023)

12.3 Hepatocellular Carcinoma Drugs Market Forecast by Type (2018-2023)

12.3.1 Global Hepatocellular Carcinoma Drugs Sales Forecast by Type (2018-2023)

12.3.2 Global Hepatocellular Carcinoma Drugs Market Share Forecast by Type (2018-2023)

12.4 Hepatocellular Carcinoma Drugs Market Forecast by Application (2018-2023)

12.4.1 Global Hepatocellular Carcinoma Drugs Sales Forecast by Application (2018-2023)

12.4.2 Global Hepatocellular Carcinoma Drugs Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source




Please fill the form below, to recieve the report sample

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*

Please fill the form below for enquiry

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*
   Our Clients
  • \


Copyright © 2020 Fior Market Research LLP, All Rights Reserved.